相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacogenomics and Translational Simulations to Bridge Indications for an Anti-Interferon-α Receptor Antibody
B. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Mechanistic Modeling of Antigen Sink Effect for Mavrilimumab Following Intravenous Administration in Patients With Rheumatoid Arthritis
Bing Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
Brandon W. Higgs et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The Pathogenesis of Systemic Sclerosis
Tamiko R. Katsumoto et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Type I interferon system activation and association with disease manifestations in systemic sclerosis
Maija-Leena Eloranta et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Pharmacotherapy of systemic sclerosis
Arnold E. Postlethwaite et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
The uncontrolled clinical trial: scientific, ethical, and practical reasons for being
Luigi Sacca
INTERNAL AND EMERGENCY MEDICINE (2010)
The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis
Alison M. Betts et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Critical role for constitutive type I interferon signaling in the prevention of cellular transformation
Hui-min Chen et al.
CANCER SCIENCE (2009)
Disease-modifying treatment in systemic sclerosis: current status
Niamh P. Quillinan et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy
Nicolas Hunzelmann et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Systemic sclerosis prevalence and comorbidities in the US, 2001-2002
Don Robinson et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Interferons and scleroderma - A new clue to understanding the pathogenesis of scleroderma?
Luiz Felipe Leomil Coelho et al.
IMMUNOLOGY LETTERS (2008)
Type I Interferon: Potential Therapeutic Target for Psoriasis?
Yihong Yao et al.
PLOS ONE (2008)
A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I Interferons and Toll-like receptor agonists
Michael R. York et al.
ARTHRITIS AND RHEUMATISM (2007)
Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients
FK Tan et al.
RHEUMATOLOGY (2006)
A critical function for type I interferons in cancer immunoediting
GP Dunn et al.
NATURE IMMUNOLOGY (2005)
Scleroderma - clinical and pathological advances
CP Denton et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2004)
Systemic and cell type-specific gene expression patterns in scleroderma skin
ML Whitfield et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
HPV DNA testing in cervical cancer screening - Results from women in a high-risk province of Costa Rica
M Schiffman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
